- Home
- DCBO vs NVAX Comparison
DCBO vs NVAX Comparison
Compare DCBO & NVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DCBO
- NVAX
- Stock Information
- Founded
- DCBO 2016
- NVAX 1987
- Country
- DCBO Canada
- NVAX United States
- Employees
- DCBO N/A
- NVAX N/A
- Industry
- DCBO
- NVAX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- DCBO
- NVAX Health Care
- Exchange
- DCBO Nasdaq
- NVAX Nasdaq
- Market Cap
- DCBO N/A
- NVAX 1.3B
- IPO Year
- DCBO 2020
- NVAX 1995
- Fundamental
- Price
- DCBO $29.29
- NVAX $6.95
- Analyst Decision
- DCBO Strong Buy
- NVAX Buy
- Analyst Count
- DCBO 7
- NVAX 6
- Target Price
- DCBO $53.29
- NVAX $17.83
- AVG Volume (30 Days)
- DCBO 88.0K
- NVAX 3.5M
- Earning Date
- DCBO 05-08-2025
- NVAX 05-09-2025
- Dividend Yield
- DCBO N/A
- NVAX N/A
- EPS Growth
- DCBO 975.00
- NVAX N/A
- EPS
- DCBO 0.86
- NVAX N/A
- Revenue
- DCBO $216,931,000.00
- NVAX $682,162,000.00
- Revenue This Year
- DCBO $13.92
- NVAX N/A
- Revenue Next Year
- DCBO $14.54
- NVAX $15.02
- P/E Ratio
- DCBO $34.06
- NVAX N/A
- Revenue Growth
- DCBO 19.96
- NVAX N/A
- 52 Week Low
- DCBO $27.61
- NVAX $3.81
- 52 Week High
- DCBO $53.86
- NVAX $23.86
- Technical
- Relative Strength Index (RSI)
- DCBO 32.62
- NVAX 38.37
- Support Level
- DCBO $29.14
- NVAX $7.47
- Resistance Level
- DCBO $32.29
- NVAX $7.81
- Average True Range (ATR)
- DCBO 1.01
- NVAX 0.35
- MACD
- DCBO 0.44
- NVAX -0.06
- Stochastic Oscillator
- DCBO 13.04
- NVAX 0.61
About NVAX Novavax Inc.
Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. It works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The company manages its business as one operating segment, the development and commercialization of vaccines. The company generates maximum revenue from the United States.